Immunome(US:IMNM)2025-03-19 20:08Financial Performance - Immunome reported a net loss of $292.96 million for the year ended December 31, 2024, compared to a net loss of $106.81 million in 2023[11]. - The accumulated deficit increased to $515.77 million as of December 31, 2024, from $222.81 million in 2023[11]. - Immunome's total operating expenses for 2024 were $314.84 million, up from $123.55 million in 2023[11]. Research and Development - Research and development expenses for 2024 were $129.54 million, significantly up from $23.09 million in 2023[11]. - The Phase 3 RINGSIDE trial for varegacestat is fully enrolled, with topline data expected in the second half of 2025[4]. - The first patient was dosed in the Phase 1 clinical trial of IM-1021 in February 2025, targeting advanced B-cell lymphomas and solid tumors[5]. - The company has three additional novel ADCs (IM-1617, IM-1335, IM-1340) in IND-enabling manufacturing[7]. Funding and Financial Position - The company completed an upsized public offering in January 2025, raising gross proceeds of $172.5 million to support clinical milestones[11]. - Cash, cash equivalents, and marketable securities totaled $217.3 million as of December 31, 2024, excluding the January 2025 financing[11]. - The projected cash runway extends into 2027, providing a solid foundation for future clinical developments[6].